3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Thrombocytopenia
3
Purpura, Thrombocytopenic, Idiopathic
2
Purpura, Thrombocytopenic
2
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Hodgkin Disease
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Bevacizumab
9
Oxaliplatin
7
Irinotecan
6
Fluorouracil
6
Nivolumab
5
Leucovorin
5
Cetuximab
5
Capecitabine
5
pembrolizumab
4
Sunitinib
4
IFL protocol
4
Drug Therapy
4
Cisplatin
4
encorafenib
3
Pemetrexed
3
Gemcitabine
3
Folfox protocol
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
trastuzumab deruxtecan
2
amminedichloro(2-methylpyridine)platinum(II)
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Levoleucovorin
2
IDRX-42
2
CGX1321
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
ulixertinib
1
tivozanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastrointestinal Neoplasms
×
romiplostim
×
Clear all
NCT03362177
2026-02-11
RECITE
Amgen
Phase 3
Completed
165 enrolled
22 charts